CSNK1A1L Antibody

What is CSNK1A1L and how does it differ from CSNK1A1?

CSNK1A1L (casein kinase 1 alpha 1-like) is a paralog of CSNK1A1 (casein kinase 1 alpha 1) that shares similar functional domains. While CSNK1A1 is located on chromosome 5q32 and functions as a putative tumor suppressor involved in cell cycle regulation, apoptosis, and autophagy, CSNK1A1L remains less characterized but potentially has overlapping functions . Both are serine/threonine protein kinases that participate in various cellular processes, with CSNK1A1 being a well-documented negative regulator of the Wnt/β-catenin pathway .

The primary differences lie in their genetic location, expression patterns, and potentially their specific roles in cellular signaling pathways. Sequence homology between these proteins can create challenges for antibody specificity, which researchers must consider when designing experiments .

What are the main applications for CSNK1A1L antibodies in research?

CSNK1A1L antibodies are primarily utilized in several key applications:

Researchers should note that the observed molecular weight (70 kDa) differs from the calculated weight (39 kDa) for CSNK1A1L, which may indicate post-translational modifications or alternative splicing variants .

How should I select an appropriate CSNK1A1L antibody for my research?

When selecting a CSNK1A1L antibody, consider these research-validated criteria:

• Experimental application: Different antibodies perform optimally in specific applications (WB, IHC, IF). Review validation data for your intended application .

• Specificity: Due to high homology between CSNK1A1L and CSNK1A1, confirm antibody specificity. Some commercial antibodies demonstrate cross-reactivity with CSNK1A1 .

• Renewable vs. polyclonal: Recombinant monoclonal antibodies offer superior reproducibility compared to polyclonal antibodies. The comprehensive study characterizing ten commercial CSNK1A1 antibodies found several high-quality renewable antibodies that successfully detect the target protein across multiple applications .

• Validation methodology: Prioritize antibodies validated using knockout cell lines and isogenic parental controls, as these provide the most reliable evidence of specificity .

• Species reactivity: Verify that the antibody has been tested in your species of interest. Many CSNK1A1L antibodies are validated for human, mouse, and rat samples .

What controls should I include when using CSNK1A1L antibodies in Western blot experiments?

For rigorous Western blot experiments with CSNK1A1L antibodies, implement these controls:

• Positive control: Include lysates from cells known to express CSNK1A1L. HeLa cells and transfected HEK-293 cells have been validated as positive controls .

• Negative control: When possible, use CSNK1A1L knockout or knockdown samples. Since complete knockout may affect cell viability, siRNA knockdown is often preferred .

• Loading control: Include housekeeping proteins (β-actin, GAPDH) to normalize protein loading.

• Molecular weight markers: Essential for verifying the observed band corresponds to the expected protein size (note that CSNK1A1L shows discrepancies between calculated and observed molecular weights) .

• Cross-reactivity control: If studying both CSNK1A1 and CSNK1A1L, use recombinant proteins of each to assess antibody specificity, as demonstrated in validation studies: "Lane 1: N-GST tagged Human CSNK1A1L full-length (aa1 to 337) recombinant protein 10ng; Lane 2: N-GST tagged Human CSNK1A1 full-length (aa1 to 337) recombinant protein 10ng" .

How can I optimize immunofluorescence protocols using CSNK1A1L antibodies?

To achieve optimal immunofluorescence results with CSNK1A1L antibodies:

• Fixation method: Use 4% paraformaldehyde (PFA) in PBS for 15 minutes at room temperature to preserve protein structure while maintaining cellular architecture .

• Permeabilization: Employ 0.1% Triton X-100 in PBS for 10 minutes at room temperature to allow antibody access to intracellular targets .

• Blocking solution: Prepare PBS with 5% BSA, 5% goat serum, and 0.01% Triton X-100 for 30 minutes at room temperature to minimize non-specific binding .

• Antibody dilution: Perform a titration experiment using recommended dilution ranges (typically 1:100-1:500) to determine optimal concentration for your specific experimental conditions .

• Visualization approach: To distinguish between non-specific staining and specific signals, the mosaic approach is recommended: "HCT 116 WT and CSNK1A1 KD cells were labelled with a green and a far-red fluorescence dye, respectively... WT and KD cells were plated as a mosaic and incubated for 24 hrs... Cells were fixed in 4% PFA" .

• Incubation conditions: For optimal results, incubate with primary antibody overnight at 4°C followed by fluorophore-conjugated secondary antibodies (1.0 μg/ml) for 1 hour at room temperature .

What are the recommended protocols for immunohistochemistry with CSNK1A1L antibodies?

For effective immunohistochemistry using CSNK1A1L antibodies:

• Tissue preparation: Use formalin-fixed, paraffin-embedded tissues sectioned at 4-6 μm thickness.

• Antigen retrieval: CSNK1A1L detection specifically benefits from TE buffer at pH 9.0, though citrate buffer at pH 6.0 can serve as an alternative .

• Antibody dilution: Start with a 1:20-1:200 dilution range, optimizing based on tissue type and expression levels .

• Incubation parameters: Optimal results typically require overnight primary antibody incubation at 4°C.

• Positive control tissues: Human testis, brain, kidney, lung, ovary, and skin tissues have been validated for CSNK1A1L detection by IHC .

• Negative controls: Include isotype controls and/or primary antibody omission controls to distinguish specific staining from background.

• Detection system: HRP-conjugated secondary antibodies with DAB (3,3'-diaminobenzidine) provide excellent visualization of CSNK1A1L in tissue sections.

Why do I observe multiple bands in Western blots using CSNK1A1L antibodies?

Multiple bands in CSNK1A1L Western blots can occur for several reasons:

• Alternative splicing: CSNK1A1 and potentially CSNK1A1L have multiple splice variants. Research has identified numerous CSNK1A1 variants in the NCBI RefSeq and Ensembl databases .

• Post-translational modifications: Phosphorylation states can alter protein migration patterns.

• Cross-reactivity: Some antibodies cross-react with both CSNK1A1 and CSNK1A1L: "The commercial CK1α-like antibody was also tested, but it showed cross-reactivity with CK1α" .

• Protein degradation: Proteolytic fragments may appear as additional bands.

• Experimental evidence: Western blot validation data from antibody manufacturers show multiple bands across different cell lines. For example, one antibody showed predicted bands of varying sizes (39 kDa, 47 kDa, 48 kDa, etc.) and observed bands at multiple weights (15 kDa, 35 kDa, 45 kDa, 95 kDa, etc.) .

To address this issue, researchers should perform validation with recombinant proteins, knockout/knockdown controls, and compare results with antibodies targeting different epitopes.

How can I differentiate between CSNK1A1 and CSNK1A1L in my experiments?

Distinguishing between these highly similar proteins requires careful experimental design:

• Antibody selection: Use antibodies raised against unique regions that don't share homology between the two proteins. Validation studies have identified antibodies with specificity for each protein .

• Knockout/knockdown controls: Generate single knockouts/knockdowns for each gene separately, as well as double knockouts/knockdowns as controls. This approach was successfully used in research: "Two clones for each single KO line and three clones for CK1α/CK1α-like double KO (dKO) line together with the WT T-REx-293 cells as a control (WT Ctrl) were selected" .

• Recombinant protein standards: Include purified recombinant proteins of both CSNK1A1 and CSNK1A1L as references in Western blots .

• mRNA analysis: Complement protein detection with RT-PCR or RNA-seq using gene-specific primers to confirm expression patterns.

• Functional assays: Utilize functional differences between the proteins, such as differential effects on Wnt/β-catenin signaling, to distinguish their activities .

What factors can affect the reproducibility of experiments using CSNK1A1L antibodies?

Several factors can impact experimental reproducibility:

• Antibody lot variation: Particularly with polyclonal antibodies, lot-to-lot variations can significantly affect results. Recombinant monoclonal antibodies provide greater consistency .

• Cell line heterogeneity: Different cell lines express varying levels of CSNK1A1L and may have different splice variants or post-translational modifications .

• Protein extraction methods: The buffer composition and cell lysis approach can affect protein conformation and epitope accessibility.

• Blocking reagents: The choice of blocking agent (BSA vs. non-fat dry milk) can influence background and specific signal. Studies have shown that "5% NFDM/TBST" is effective for blocking in Western blots targeting these proteins .

• Detection systems: The sensitivity and dynamic range of detection methods (ECL substrates, fluorescent secondary antibodies) impact signal quantification.

• Experimental protocols: Standardized protocols are crucial for reproducibility, as demonstrated by the comprehensive antibody characterization study that employed consistent methods across multiple antibodies .

How can CSNK1A1L antibodies be used to study Wnt/β-catenin signaling pathways?

CSNK1A1L antibodies enable sophisticated investigation of Wnt/β-catenin pathway regulation:

• Co-immunoprecipitation studies: Use CSNK1A1L antibodies to identify protein-protein interactions within the destruction complex (including APC, Axin, and GSK3β) .

• Phosphorylation site analysis: Combine CSNK1A1L antibodies with phospho-specific β-catenin antibodies to assess kinase activity on the Ser-45 phosphorylation site, which is crucial for β-catenin degradation .

• Subcellular localization: Employ immunofluorescence with CSNK1A1L antibodies to track protein localization changes upon Wnt pathway activation .

• Rescue experiments: As demonstrated in research, conduct functional studies using knockout/knockdown cells with reintroduction of specific variants: "We prepared CK1α-v1(K160N) and CK1α-v12(K160N) harboring the mutation in the NLS within the L-segment" .

• Signal transduction analysis: Utilize CSNK1A1L antibodies in combination with other pathway components to map the sequence of phosphorylation events following Wnt stimulation.

What are the current challenges in studying CSNK1A1L splice variants with available antibodies?

Researchers face several challenges when investigating CSNK1A1L splice variants:

• Variant-specific detection: Most commercial antibodies cannot distinguish between splice variants, as they typically target conserved regions.

• Identification complexity: The existence of multiple splice variants (as documented for CSNK1A1 in databases) complicates interpretation of Western blot bands .

• Functional characterization: Different variants may have distinct subcellular localizations and functions, requiring specialized tools for differentiation.

• Epitope accessibility: Structural differences between variants can affect antibody binding efficiency.

• Cross-reactivity issues: Studies have noted: "The commercial CK1α-like antibody was also tested, but it showed cross-reactivity with CK1α" .

To address these challenges, researchers should consider:

• Developing splice variant-specific antibodies targeting unique junction sequences

• Employing RNA-based methods alongside protein detection

• Using tagged recombinant variants for overexpression studies

• Conducting variant-specific knockdown experiments

How can CSNK1A1L antibodies contribute to cancer research and potential therapeutic development?

CSNK1A1L antibodies offer valuable tools for cancer research applications:

• Biomarker identification: CSNK1A1 has been identified as a putative tumor suppressor, and antibodies enable assessment of expression levels across various cancer types .

• Diagnostic applications: IHC with validated CSNK1A1L antibodies can potentially aid in cancer classification, as demonstrated by positive IHC detection in "human breast cancer tissue, human lung cancer tissue" .

• Drug target validation: Since CSNK1A1 is involved in the CGAS-STING pathway and inhibits overactivation of type I interferon signaling, antibodies can help validate therapeutic targeting strategies .

• Therapy response prediction: Expression and phosphorylation status detected by specific antibodies may correlate with sensitivity to certain therapies, particularly in myelodysplastic syndromes .

• Mechanistic studies: Antibodies facilitate investigation of CSNK1A1L's role in cell cycle regulation, apoptosis, and autophagy pathways that are frequently dysregulated in cancer .

• Screening assays: Developing functional assays with CSNK1A1L antibodies can support high-throughput screening for compounds that modulate its activity or expression.

For researchers designing cancer-focused studies, combining CSNK1A1L antibody-based approaches with genetic manipulation and functional readouts provides the most comprehensive insights into its role in tumorigenesis and potential as a therapeutic target.

What are the recommendations for combining CSNK1A1L antibodies with other research techniques for comprehensive protein characterization?

For comprehensive CSNK1A1L characterization, consider these integrated approaches:

• Mass spectrometry integration: Use immunoprecipitation with validated CSNK1A1L antibodies followed by mass spectrometry to identify post-translational modifications and interacting proteins.

• CRISPR-Cas9 genome editing: Generate knockout or knock-in cell lines as definitive controls for antibody validation, following approaches used in published research: "Multiple clones were isolated for each type of KO line, and monoclonal cell lines were established. The cell lines were thoroughly validated by restriction fragment length polymorphism, Western blotting (WB), and next generation sequencing" .

• Proximity labeling techniques: Combine CSNK1A1L antibodies with BioID or APEX2 approaches to identify proximal interacting proteins in living cells.

• Live-cell imaging: Correlate fixed-cell antibody staining patterns with live-cell dynamics using fluorescently tagged CSNK1A1L.

• Kinase activity assays: Pair immunoprecipitation using CSNK1A1L antibodies with in vitro kinase assays to assess enzymatic activity under various conditions.

• Super-resolution microscopy: Apply validated antibodies in techniques like STORM or PALM for nanoscale localization studies.

• Chromatin immunoprecipitation: For nuclear CSNK1A1L variants, combine with ChIP-seq to identify potential DNA interactions or chromatin association.